The addition of the bispecific T-cell engager blinatumomab (Blincyto, Amgen) to the consolidation regimen of patients with previously untreated B-lineage acute lymphoblastic leukemia (ALL) provides an overall survival benefit whether or not patients achieve negative minimal residual disease (MRD) status after induction treatment, according to interim results of a phase 3 trial.
Blinatumomab has been associated with a survival benefit in MRD-positive patients. However, this study suggests